<DOC>
	<DOC>NCT01048333</DOC>
	<brief_summary>- Primary objective is to evaluate time to onset of effect of formoterol, 9 μg single dose,compared with salmeterol, 50 μg single dose, in patients with moderate COPD.Forced Expiratory Volume in 1 second (FEV1) measured by spirometry 5 minutes postdose. - Secondary efficacy variables: Average FEV1 during the first 15 minutes (area under the FEV1 curve from 0 to 15 minutes), Average FEV1 during 120 minutes (area under the FEV1 curve from 0 to 120 minutes)</brief_summary>
	<brief_title>Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>A clinical diagnosis of COPD according to GOLD guidelines, and current COPD symptoms A current or previous smoking history equivalent to 10 or more packs per year (1 pack year = 20 cigarettes smoked per day for one year). Documented use of a shortacting inhaled bronchodilator (β2agonist or anticholinergics) as reliever medication. A history and/or current diagnosis of asthma. Patients who have experienced COPD exacerbation requiring hospitalisation and/or a course of antibiotics and/or a course of systemic steroid within 30 days (from end of exacerbation treatment) prior to Visit 1 and/or during the runin period. A history and/or current diagnosis of atopic diseases such as allergic rhinitis or eczema before the age of 40.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Onset of effect</keyword>
	<keyword>COPD</keyword>
	<keyword>Oxis Turbuhaler</keyword>
</DOC>